Division of Otolaryngology-Head and Neck, Department of Surgery, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin, USA.
Laryngoscope. 2010 Mar;120(3):537-45. doi: 10.1002/lary.20782.
OBJECTIVES/HYPOTHESIS: To determine the effectiveness of bone marrow mesenchymal stem cell (BM-MSC) transplantation in isolation or within a synthetic extracellular matrix (sECM) for tissue regeneration of the scarred vocal fold lamina propria.
In vitro stability and compatibility of mouse BM-MSC embedded in sECM was assessed by flow cytometry detection of BM-MSC marker expression and proliferation. Eighteen rats were subjected to vocal fold injury bilaterally, followed by 1 month post-treatment with unilateral injections of saline or sECM hydrogel (Extracel; Glycosan BioSystems, Inc., Salt Lake City, UT), green fluorescence protein (GFP)-mouse BM-MSC, or BM-MSC suspended in sECM. Outcomes measured 1 month after treatment included procollagen-III, fibronectin, hyaluronan synthase-III (HAS3), hyaluronidase (HYAL3), smooth muscle actin (SMA), and transforming growth factor-beta 1(TGF-beta1) mRNA expression. The persistence of GFP BM-MSC, proliferation, apoptosis, and myofibroblast differentiation was assessed by immunofluorescence.
BM-MSC grown in vitro within sECM express Sca-1, are positive for hyaluronan receptor CD44, and continue to proliferate. In the in vivo study, groups injected with BM-MSC had detectable GFP-labeled BM-MSC remaining and showed proliferation and low apoptotic or myofibroblast markers compared to the contralateral side. Embedded BM-MSC in the sECM group exhibited increased levels of procollagen III, fibronectin, and TGF-beta1. BM-MSC within sECM downregulated the expression of SMA compared to BM-MSC alone and exhibited upregulation of HYAL3 and no change in HAS3 compared to saline.
Treatment of vocal fold scarring with BM-MSC injected in a sECM displayed the most favorable outcomes in ECM production, hyaluronan metabolism, myofibroblast differentiation, and production of TGF-beta1. Furthermore, the combined treatment had no detectable cytotoxicity and preserved local cell proliferation.
目的/假设:确定骨髓间充质干细胞(BM-MSC)单独或在合成细胞外基质(sECM)内移植用于瘢痕性声带固有层组织再生的效果。
通过流式细胞术检测 BM-MSC 标志物表达和增殖,评估小鼠 BM-MSC 嵌入 sECM 的体外稳定性和相容性。18 只大鼠双侧声带受伤,1 个月后单侧注射生理盐水或 sECM 水凝胶(Extracel;Glycosan BioSystems,Inc.,盐湖城,犹他州)、绿色荧光蛋白(GFP)-鼠 BM-MSC 或悬浮在 sECM 中的 BM-MSC。治疗后 1 个月测量的结果包括前胶原蛋白 III、纤维连接蛋白、透明质酸合酶-III(HAS3)、透明质酸酶(HYAL3)、平滑肌肌动蛋白(SMA)和转化生长因子-β1(TGF-β1)mRNA 表达。通过免疫荧光评估 GFP BM-MSC 的持久性、增殖、凋亡和肌成纤维细胞分化。
在 sECM 内体外生长的 BM-MSC 表达 Sca-1,对透明质酸受体 CD44 呈阳性,并持续增殖。在体内研究中,与对侧相比,注射 BM-MSC 的组可检测到残留的 GFP 标记的 BM-MSC,并显示增殖和低凋亡或肌成纤维细胞标志物。sECM 组中的嵌入 BM-MSC 表现出较高水平的前胶原蛋白 III、纤维连接蛋白和 TGF-β1。与单独的 BM-MSC 相比,sECM 内的 BM-MSC 下调 SMA 的表达,并表现出 HYAL3 的上调和 HAS3 无变化与生理盐水相比。
用注射到 sECM 中的 BM-MSC 治疗声带瘢痕显示出在 ECM 产生、透明质酸代谢、肌成纤维细胞分化和 TGF-β1 产生方面最有利的结果。此外,联合治疗没有可检测的细胞毒性并保留局部细胞增殖。